Comparative Pharmacology
Head-to-head clinical analysis: BUPRENEX versus TALWIN NX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPRENEX versus TALWIN NX.
BUPRENEX vs TALWIN NX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at mu-opioid receptors; weak antagonist at kappa-opioid receptors.
Pentazocine is a mixed agonist-antagonist opioid analgesic that acts as an agonist at kappa opioid receptors and as an antagonist or partial agonist at mu opioid receptors. Naloxone is added to prevent intravenous abuse but has no oral bioavailability.
0.3 mg intramuscularly or intravenously every 6 hours as needed for pain; may repeat once after 30-60 minutes if needed.
1 tablet (pentazocine 50 mg/naloxone 0.5 mg) orally every 3-4 hours as needed for pain; maximum 12 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 37 hours (range 20-70 hours) due to slow dissociation from mu-opioid receptors, contributing to prolonged clinical effects.
2-3 hours (terminal) for pentazocine; naloxone half-life 1-1.5 hours. Clinically, duration limited by pentazocine's shorter half-life.
Buprenorphine is primarily eliminated via fecal excretion (70%) as unchanged drug and metabolites, with renal excretion accounting for approximately 10-30% of the dose.
Renal: ~60% as unchanged drug and glucuronide conjugates. Biliary/fecal: ~20% as metabolites. Total: 80% eliminated within 72 hours.
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist/Antagonist